

Greek Amulance Service Completes Standardization to ZOLL Medical Resuscitation Equipment

ZOLL Medical Corporation completed the inservice of resuscitation equipment to the Greek Ambulance Service, known as EKAV, operated by the Government of Greece. Under the exclusive contract through its distributor J. Ladakas, S.A., ZOLL has outfitted a total of 295 new ambulance vehicles, 25 fast-response motorbikes, and four local EKAV medical centers with a combination of ZOLL M Series and AED Plus defibrillators. In addition, 200 existing ambulances currently in service have been upgraded with ZOLL AED Plus defibrillators, bringing the total number of units deployed to 524.

CHELMSFORD, MA (PRWEB) August 16, 2004 -- ZOLL Medical Corporation (NASDAQ: ZOLL), a manufacturer of resuscitation devices and software solutions, announced today that it has completed the inservice of resuscitation equipment to the Greek Ambulance Service, known as EKAV, operated by the Government of Greece. Under the exclusive contract through its distributor J. Ladakas, S.A., ZOLL has outfitted a total of 295 new ambulance vehicles, 25 fast-response motorbikes, and four local EKAV medical centers with a combination of ZOLL M Series and AED Plus defibrillators. In addition, 200 existing ambulances currently in service have been upgraded with ZOLL AED Plus defibrillators, bringing the total number of units deployed to 524.

Furthermore, in an earlier tender, J. Ladakas, S.A. has also supplied an additional 50 AED Plus units for the forthcoming Olympics in Greece. These defibrillators will be used to support the games taking place from August 13 to August 29, and will be distributed at certain public venues and operated by medical volunteers.

Commenting on these contracts, Richard A. Packer, President and Chief Executive Officer of ZOLL, said, $\hat{A} \square$ These were significant wins for ZOLL because our resuscitation equipment has now been deployed on all ambulances in the country of Greece. The exclusive agreement demonstrates EKAV $\hat{A} \square$ s belief in the strength and reliability of ZOLL $\hat{A} \square$ s resuscitation equipment. Additionally, the separate 50 AED Plus order will help prepare for sudden cardiac arrest events that may happen during the upcoming games. These units will be deployed in public venues, where approximately 150,000 people will attend daily. Having these units deployed may mean that victims of sudden cardiac arrest will receive appropriate treatment sooner, increasing the chance of survival. $\hat{A} \square$

When a victim collapses from sudden cardiac arrest, rescuers do not know whether defibrillation or CPR is the appropriate therapy until an AED is attached and the victim $\hat{A} \square s$ heart is analyzed. About half of all cardiac arrest victims that suddenly collapse initially require defibrillation. For other victims, however, who may have non-shockable heart rhythms, the critical action for survival is effective CPR.

The ZOLL AED Plus is the only AED that helps rescuers perform effective CPR because it allows them to see and hear how well they are performing the rate and depth of chest compressions during CPR. This real-time feedback mechanism makes the ZOLL AED Plus the only AED that can help assess and treat nearly every sudden cardiac arrest victim, making it the only Full-Rescue AED available today.

About ZOLL Medical Corporation

ZOLL Medical Corporation (NASDAQ: ZOLL) designs, manufactures, markets, and/or sells non-invasive



resuscitation devices and software solutions. They include pacing and defibrillation devices (ZOLLÂ \Box s M Series \Box and AED Plus \Box , and LIFECOR, Inc. \Box s LifeVest \Box and Life-Padz \Box WCD 3000S Wearable Defibrillators), circulatory assist devices (Advanced Circulatory Systems, Inc. \Box s ResQPOD® Circulatory Enhancer and Revivant Corporation \Box s AutoPulse \Box); and a fluid resuscitation product called the Power Infuser \Box , manufactured by Infusion Dynamics, a division of ZOLL. These devices help healthcare professionals, emergency medical service providers, and first responders diagnose and treat victims of trauma, as well as sudden cardiac arrest.

Additionally, through its subsidiary ZOLL Data Systems, ZOLL designs and markets software that automates the collection and management of both clinical and non-clinical data. With direct operations, international offices, and business partners in all of the worldÂ \Box s major markets, ZOLL markets and sells its products in more than 140 countries. For more information, visit <u>www.zoll.com</u> or call +1 (978) 421-9655.

Certain statements contained in this press release, including statements regarding the anticipated development of the CompanyÂ \Box s business, our ability to differentiate our products from others on the market, and other statements contained herein regarding matters that are not historical facts, are "forward-looking" statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled "Risk Factors" in the CompanyÂ \Box s Quarterly Report on Form 10-Q filed with the SEC on May 19, 2004.

Copyright © 2004 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. AED Plus, Life-Padz, M Series, and Power Infuser are trademarks of ZOLL Medical Corporation. The LifeVest System is a trademark of LIFECOR, Inc. The ResQPOD is a registered trademark of Advanced Circulatory Systems, Inc. The AutoPulse Resuscitation System is a trademark of Revivant Corporation. ZOLL is a registered trademark of ZOLL Medical Corporation. All trademarks are property of their respective owners.

###



Contact Information Robert Minicucci ZOLL MEDICAL CORP. http://www.zoll.com 978.421.9832

Online Web 2.0 Version You can read the online version of this press release <u>here</u>.

Page 3/3